Michelle Mott

783 total citations
9 papers, 218 citations indexed

About

Michelle Mott is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michelle Mott has authored 9 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 6 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michelle Mott's work include Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (4 papers) and HER2/EGFR in Cancer Research (2 papers). Michelle Mott is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Viral-associated cancers and disorders (4 papers) and HER2/EGFR in Cancer Research (2 papers). Michelle Mott collaborates with scholars based in United States. Michelle Mott's co-authors include Leslie Popplewell, Tanya Siddiqi, Robert Chen, Sandra H. Thomas, Joycelynne Palmer, Peter Martin, Stephen J. Forman, John P. Leonard, Firoozeh Sahebi and Young Kim and has published in prestigious journals such as Blood, Haematologica and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Michelle Mott

9 papers receiving 214 citations

Peers

Michelle Mott

PFM

ONCOL

NEURO

GENET

MB

Patricia Franchi France

Lauris Gastaud France

João Raposo Portugal

Yasir Khan United States

Jun Amaki Japan

Shalal Sadullah United Kingdom

Huiqiang Huang China

Tetiana Skrypets Italy

Sarah Reinke Germany

Christine Mauz‐Koerholz Germany

Patricia Franchi France

Michelle Mott

120 ×0.8

PFM

85 ×0.6

ONCOL

54 ×0.9

NEURO

36 ×0.7

GENET

23 ×0.6

MB

Citations per year, relative to Michelle Mott Michelle Mott (= 1×) peers Patricia Franchi

Countries citing papers authored by Michelle Mott

Since Specialization

Citations

This map shows the geographic impact of Michelle Mott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Mott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Mott more than expected).

Fields of papers citing papers by Michelle Mott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Mott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Mott. The network helps show where Michelle Mott may publish in the future.

Co-authorship network of co-authors of Michelle Mott

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Mott. A scholar is included among the top collaborators of Michelle Mott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Mott. Michelle Mott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Anderson, Blake, et al.. (2025). Development and Evaluation of a Model to Manage Patient Portal Messages. NEJM AI. 2(3). 3 indexed citations

2.

Chen, Robert, Paul Frankel, Leslie Popplewell, et al.. (2015). A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 100(3). 357–362. 61 indexed citations

3.

Chen, Robert, Joycelynne Palmer, Peter Martin, et al.. (2015). Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 21(12). 2136–2140. 94 indexed citations

4.

Chen, Robert, Joycelynne Palmer, Peter Martin, et al.. (2015). Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood. 126(23). 519–519. 8 indexed citations

5.

Chen, Robert W., Joycelynne Palmer, Peter Martin, et al.. (2014). Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood. 124(21). 501–501. 11 indexed citations

6.

Chen, Robert, Paul Frankel, Leslie Popplewell, et al.. (2013). Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. Blood. 122(21). 4398–4398. 2 indexed citations

7.

Pan, Janet, Michelle Mott, Bixin Xi, et al.. (2012). Phase I study of nelfinavir in liposarcoma. Cancer Chemotherapy and Pharmacology. 70(6). 791–799. 25 indexed citations

8.

Chen, Robert W., Joycelynne Palmer, Tanya Siddiqi, et al.. (2012). Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. Blood. 120(21). 3699–3699. 4 indexed citations

9.

Kaplan, Barbara, et al.. (2011). Design and Implementation of an Interdisciplinary Pediatric Mock Code for Undergraduate and Graduate Nursing Students. CIN Computers Informatics Nursing. 29(9). 531–538. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact